Results 71 to 80 of about 12,265 (153)

Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. [PDF]

Indian J Ophthalmol
Chakraborty D, Sinha TK, Boral S, Das A.
europepmc   +1 more source

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study

Clinical Ophthalmology
Debdulal Chakraborty,1 Tushar Kanti Sinha,1 Sourav Sinha,2 Rupak Kanti Biswas,2 Aniruddha Maiti,3 Krishnendu Nandi,2 Dinesh Rungta,1 Ranabir Bhattacharya1 1Vitreo-Retina Services, Disha Eye Hospitals, Kolkata, WB, India; 2Vitreo-retina Services ...
Chakraborty D, Sinha TK, Sinha S, Biswas RK, Maiti A, Nandi K, Rungta D, Bhattacharya R   +7 more
doaj  

Computational modeling of intravitreal ranibizumab kinetics: Predicting macular drug concentration and half-life. [PDF]

PLoS One
Chowdhury JM.
europepmc   +1 more source

Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study). [PDF]

Pharmaceuticals (Basel)
Chakraborty D, Sinha TK, Sinha S, Biswas RK, Das A, Maiti A, Bhattacharya R, Dan S, Rungta D, Das S.   +9 more
europepmc   +1 more source

Anti-VEGF therapy for posterior segment disorders: The story so far…. [PDF]

Indian J Ophthalmol
Chawla R.
europepmc   +1 more source

From bench to bed: The evolution of anti-vascular endothelial growth factor therapies. [PDF]

Indian J Ophthalmol
Sen A, Kohli G, Agarwal A, Chauhan R.
europepmc   +1 more source

Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead. [PDF]

Indian J Ophthalmol
Mishra C, Mohanty N, Purohit S, Orugonda U, Patil V.   +4 more
europepmc   +1 more source

Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]

Front Public Health
Hamida JA, Alkhatib NS, Hammour KA, Halloush S, Kurdi A, Balkhi B, Alfayez OM, Mousa R.   +7 more
europepmc   +1 more source

Ten-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization. [PDF]

Medicine (Baltimore)
Kung YH, Peng KL, Shih LY, Wu TT.
europepmc   +1 more source

Comparison of the effectiveness of ranibizumab monotherapy vs. combined panretinal photocoagulation on the regression of neovascularization in proliferative diabetic retinopathy. [PDF]

Front Med (Lausanne)
Wang Y, Wang L, Zheng Z, Xu J, Zhang Z.
europepmc   +1 more source